Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Neurosense Therapeutics Ltd's Competitiveness

Name: Neurosense Therapeutics Ltd Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Neurosense Therapeutics Ltd (NRSN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2025

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/NRSN/competitors                    

                        https://api.csimarket.com/api/v1/companies/NRSN/relationships                    

                        https://api.csimarket.com/api/v1/companies/NRSN/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Neurosense Therapeutics Ltd's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Neurosense Therapeutics Ltd	-	-	-	Yes
High-Confidence Competitors (9)
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

NRSN Stock Performance relative to its Competitors

NRSN Competitors (weighted) Percent change over the selected range

Neurosense Therapeutics Ltd's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(5 of 8)

Similar-Size
(1 of 10)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Neurosense Therapeutics Ltd	459.30 %	Outperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (8)	40.4%	63.2%
Similar-Size Competitors (10)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Neurosense Therapeutics Ltd's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

NRSN Stock Performance relative to High-Confidence Competitors

NRSN High-Confidence Competitors (equal-weighted, 10) Percent change over the selected range

NRSN Stock Performance relative to Similar-Size Competitors

NRSN Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Neurosense Therapeutics Ltd's Comment on Competition and Industry Peers

The company operates in the biopharmaceutical industry, which is characterized by rapid technological change and significant competition. Potential competitors include large, experienced companies with substantial financial resources, research and development capabilities, manufacturing capacity, personnel, marketing expertise, brand recognition, and regulatory approval experience. These competitors may develop new drugs or seek approval for existing drugs targeting the same indications as the company. The company is aware of other entities developing potentially disease-modifying therapeutics for Amyotrophic Lateral Sclerosis (ALS).

Competitor data is not yet available for Neurosense Therapeutics Ltd.

Neurosense Therapeutics Ltd's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Amylyx Pharmaceuticals Inc.	Named by the company	85%	2022 to 2026	3
Genentech	Named by the company	85%	2022 to 2026	3
Takeda	Named by the company	85%	2022 to 2026	3
Coya Therapeutics Inc	Named by the company	85%	2022 to 2026	3
Biogen Inc.	Named by the company	85%	2022 to 2026	3
Prilenia Therapeutics B.V	Named by the company	85%	2022 to 2026	3
Apellis Pharmaceuticals	Named by the company	85%	2022 to 2026	3
Prevail	Named by the company	85%	2022 to 2026	3
AB Science SA	Named by the company	85%	2022 to 2026	3
Eli Lilly	Named by the company	85%	2022 to 2026	3
Prothena	Named by the company	85%	2022 to 2026	3
AstraZeneca	Named by the company	85%	2022 to 2026	3
Prevail/Eli Lilly	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Neurosense Therapeutics Ltd's named competitors require a Commercial License.

Unlock Commercial Access

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.